Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine ...

The vaccine will only be available to those at high risk from COVID—excluding those who may need it to protect a relative or ...

China on Sunday announced anti-dumping duties as high as 74.9% on imports of POM copolymers, a type of engineering plastic, ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

In its Friday approval letter, the FDA didn’t explain the restrictions although they reflect skepticism about ...

This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

The US Food and Drug Administration cleared the shot for adults ... an approach he said has “never worked” for respiratory ...

The head of the Food and Drug Administration said the agency will soon unveil a new framework detailing what companies must ...

The U.S. Food and Drug Administration approved Novavax’s Covid-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.